熱門資訊> 正文
Immunocore错过第四季度盈利
2026-02-25 20:10
- Immunocore press release (IMCR): Q4 GAAP EPS of -$0.60 misses by $0.42.
- Revenue of $104.48M (+24.3% Y/Y) misses by $3.29M.
- Cash, cash equivalents and marketable securities of $864.2 million as of December 31, 2025.
More on Immunocore
- Immunocore Holdings plc (IMCR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Seeking Alpha’s Quant Rating on Immunocore
- Historical earnings data for Immunocore
- Financial information for Immunocore
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。